{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Osteoporosis+Postmenopausal&page=2",
    "query": {
      "condition": "Osteoporosis Postmenopausal",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Osteoporosis+Postmenopausal&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T00:27:04.525Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00130403",
      "title": "OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal"
      ],
      "interventions": [
        {
          "name": "risedronate sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "55 Years to 85 Years · Female only"
      },
      "enrollment_count": 290,
      "start_date": "2004-03",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2011-01-11",
      "last_synced_at": "2026-09-30T00:27:04.525Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00130403"
    },
    {
      "nct_id": "NCT00221312",
      "title": "Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Perimenopausal Bone Loss"
      ],
      "interventions": [
        {
          "name": "Fosamax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "54 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 54 Years · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2002-05",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2008-05-08",
      "last_synced_at": "2026-09-30T00:27:04.525Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00221312"
    },
    {
      "nct_id": "NCT01709110",
      "title": "VERtebral Fracture Treatment Comparisons in Osteoporotic Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postmenopausal Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Teriparatide",
          "type": "DRUG"
        },
        {
          "name": "Risedronate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Calcium",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 1366,
      "start_date": "2012-10",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2019-09-23",
      "last_synced_at": "2026-09-30T00:27:04.525Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Concord, California • Fresno, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01709110"
    },
    {
      "nct_id": "NCT02176382",
      "title": "Denosumab and Teriparatide Study (DATA-HD and DATA-EX)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postmenopausal Osteoporosis"
      ],
      "interventions": [
        {
          "name": "denosumab",
          "type": "DRUG"
        },
        {
          "name": "teriparatide",
          "type": "DRUG"
        },
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 76,
      "start_date": "2014-08",
      "completion_date": "2020-02",
      "has_results": true,
      "last_update_posted_date": "2021-02-09",
      "last_synced_at": "2026-09-30T00:27:04.525Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02176382"
    },
    {
      "nct_id": "NCT00926380",
      "title": "Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "denosumab",
          "type": "DRUG"
        },
        {
          "name": "teriparatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 94,
      "start_date": "2009-06",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-06-29",
      "last_synced_at": "2026-09-30T00:27:04.525Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00926380"
    },
    {
      "nct_id": "NCT05853354",
      "title": "Comparative Efficacy, Safety, PK, and Immunogenicity Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal"
      ],
      "interventions": [
        {
          "name": "Denosumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "60 Years to 90 Years · Female only"
      },
      "enrollment_count": 392,
      "start_date": "2023-04-05",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2024-04-26",
      "last_synced_at": "2026-09-30T00:27:04.525Z",
      "location_count": 3,
      "location_summary": "Thousand Oaks, California • Hialeah, Florida • Fort Worth, Texas",
      "locations": [
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05853354"
    },
    {
      "nct_id": "NCT01870115",
      "title": "Melatonin-Micronutrients for Osteopenia Treatment Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteoporosis",
        "Osteopenia"
      ],
      "interventions": [
        {
          "name": "Fiber Pill",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Melatonin, Strontium citrate, Vitamins D3 and K2",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Duquesne University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 23,
      "start_date": "2013-08",
      "completion_date": "2017-02-09",
      "has_results": false,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-09-30T00:27:04.525Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01870115"
    },
    {
      "nct_id": "NCT00439244",
      "title": "Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Teriparatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "89 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 89 Years · Female only"
      },
      "enrollment_count": 412,
      "start_date": "2006-12",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2011-04-20",
      "last_synced_at": "2026-09-30T00:27:04.525Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00439244"
    },
    {
      "nct_id": "NCT00709540",
      "title": "A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "ACE-011 or placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 85 Years · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2008-01",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2021-07-21",
      "last_synced_at": "2026-09-30T00:27:04.525Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00709540"
    },
    {
      "nct_id": "NCT00959764",
      "title": "A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal"
      ],
      "interventions": [
        {
          "name": "Oral Calcitonin Tablets",
          "type": "DRUG"
        },
        {
          "name": "Intranasal Calcitonin",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets and placebo intranasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarsa Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 565,
      "start_date": "2009-06",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-09-30T00:27:04.525Z",
      "location_count": 9,
      "location_summary": "Huntsville, Alabama • Oakland, California • Palm Desert, California + 6 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00959764"
    }
  ]
}